【摘要】 目的分析骨肉瘤患者大剂量甲氨蝶呤化疗肝功能异常及其血浓度分布特点,探讨肝肝功能异常与甲氨蝶呤血浓度的相关性。方法回顾性收集30例骨肉瘤患者大剂量甲氨蝶呤化疗肝功能指标及化疗后0、24、48和72 h的甲氨蝶呤血浓度,统计分析化疗后肝功能异常情况及其与甲氨蝶呤不同时间点血药浓度的相关性。结果大剂量甲氨蝶呤化疗后肝功能异常总发生率为84.62%,Ⅱ级及Ⅱ级以上占44.23%;化疗后肝功能指标ALT、AST与甲氨蝶呤化疗后0 h和24 h的血药浓度呈正相关,而与48 h和72 h血药浓度相关性不大。结论大剂量甲氨蝶呤化疗引起的肝功能异常发生率高,0 h和24 h血药浓度与大剂量甲氨蝶呤化疗引起的肝功能异常具有显著相关性。更多还原

【Abstract】 Objective To analyze the characteristics of abnormal liver function and the distribution of plasma concentration of high dose methotrexate in patients with osteosarcoma, and to explore the correlation between abnormal liver function and plasma concentration of methotrexate.Methods The liver function and plasma concentration of methotrexate at 0,24,48 and 72 h of 30 patients with osteosarcoma treated with high dose methotrexate were collected retrospectively.The correlation of liver function abnormality and plasma concentration of methotrexate at different time points were statistically analyzed.Results The total incidence of liver function abnormality after high dose methotrexate chemotherapy was 84.62%,including 44.23% of grade Ⅱ and above.ALT and AST were positively correlated with plasma concentration of methotrexate at 0 h and 24 h after chemotherapy, but not correlated with plasma concentration of methotrexate at 48 h and 72 h.Conclusion The incidence of liver function abnormality induced after high dose methotrexate chemotherapy is very high.The plasma concentration of methotrexate at 0 h and 24 h was significantly correlated to liver function abnormality induced by high dose methotrexate chemotherapy.更多还原